EP Patent

EP3763370A1 — Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline

Assigned to Allergan Inc · Expires 2021-01-13 · 5y expired

What this patent protects

The present invention relates to a pharmaceutical composition for use in a method of treating hyperemia, wherein the composition comprises a therapeutically effective amount of 7-(1H-lmidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline, or the individual enantiomers thereof, or the …

USPTO Abstract

The present invention relates to a pharmaceutical composition for use in a method of treating hyperemia, wherein the composition comprises a therapeutically effective amount of 7-(1H-lmidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline, or the individual enantiomers thereof, or the individual tautomers thereof, or a pharmaceutically acceptable salt thereof.

Drugs covered by this patent

Patent Metadata

Patent number
EP3763370A1
Jurisdiction
EP
Classification
—
Expires
2021-01-13
Drug substance claim
No
Drug product claim
No
Assignee
Allergan Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.